TY - JOUR
T1 - Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon
AU - Fokam, Joseph
AU - Salpini, Romina
AU - Santoro, Maria Mercedes
AU - Cento, Valeria
AU - Perno, Carlo Federico
AU - Colizzi, Vittorio
AU - Ndumbe, Peter Martins
AU - Fokunang Ntungen, Charles
AU - Ndiang Tetang, Suzie Moyo
AU - Nanfack, Aubin Joseph
AU - Takou Komego, Désiré Augustin
AU - Cappelli, Giulia
PY - 2011/12
Y1 - 2011/12
N2 - Background: Scale-up to antiretroviral therapy (ART) requires surveillance for HIV drug resistance. With the goal of attaining 100% pediatric ART coverage in Cameroon, strategies to limit the spread of HIV resistance among children are very important. Methods: From June 2009 through February 2011, 92 HIV-1-infected children (41 ART-naive, 51 failing first-line ART) living in Yaoundé, Cameroon, were enrolled; HIV-1 Prot-RT genotypic resistance testing (GRT) was performed using an inhouse assay. Among 40 children failing first-line ART, treatment response was evaluated at weeks 24 and 48 after treatment was changed, based on GRT results. Results: The mean age was 72 months both for children who were drug-naive and those failing ART (range: 3-144 and 12-144, respectively), with a mean viremia of 5.59 log and 4.71 log RNA copies/mL, a median CD4 of 17% (588 cells/μL) and 23% (719 cells/μL), respectively. Median time-to-treatment failure was 610 days. A prevalence of 4.9% and 90% drug resistance was observed, respectively, among children who were drug-naive and those failing first-line ART, with circulating recombinant form CRF02-AG as the most prevalent clade (58.6% and 62%, respectively). After a change to GRT-based treatment, more than 90% of children had viremia
AB - Background: Scale-up to antiretroviral therapy (ART) requires surveillance for HIV drug resistance. With the goal of attaining 100% pediatric ART coverage in Cameroon, strategies to limit the spread of HIV resistance among children are very important. Methods: From June 2009 through February 2011, 92 HIV-1-infected children (41 ART-naive, 51 failing first-line ART) living in Yaoundé, Cameroon, were enrolled; HIV-1 Prot-RT genotypic resistance testing (GRT) was performed using an inhouse assay. Among 40 children failing first-line ART, treatment response was evaluated at weeks 24 and 48 after treatment was changed, based on GRT results. Results: The mean age was 72 months both for children who were drug-naive and those failing ART (range: 3-144 and 12-144, respectively), with a mean viremia of 5.59 log and 4.71 log RNA copies/mL, a median CD4 of 17% (588 cells/μL) and 23% (719 cells/μL), respectively. Median time-to-treatment failure was 610 days. A prevalence of 4.9% and 90% drug resistance was observed, respectively, among children who were drug-naive and those failing first-line ART, with circulating recombinant form CRF02-AG as the most prevalent clade (58.6% and 62%, respectively). After a change to GRT-based treatment, more than 90% of children had viremia
KW - antiretroviral drug resistance
KW - Cameroon
KW - children
KW - human immunodeficiency virus
UR - http://www.scopus.com/inward/record.url?scp=81855221740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81855221740&partnerID=8YFLogxK
U2 - 10.1097/INF.0b013e31822db54c
DO - 10.1097/INF.0b013e31822db54c
M3 - Article
C2 - 21817951
AN - SCOPUS:81855221740
VL - 30
SP - 1062
EP - 1068
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
SN - 0891-3668
IS - 12
ER -